Identification of novel metoclopramide metabolites in humans: In vitro and in vivo studies

Drug Metabolism and Disposition

Volumn 38, Issue 8, 2010, Pages 1295-1307

  Argikar, Upendra A ^a   Gomez, Javier ^b   Ung, Din ^c   Parkman, Henry P ^b   Nagar, Swati ^c  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TEMPLE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DRUG METABOLITE; GLUCURONOSYLTRANSFERASE; METOCLOPRAMIDE;

ADULT; ARTICLE; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG OXIDATION; DRUG STRUCTURE; DRUG URINE LEVEL; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; MALE; MASS SPECTROMETER; NORMAL HUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; STOMACH PARESIS;

ANTIEMETICS; CYTOSOL; HUMANS; MALE; METOCLOPRAMIDE; MICROSOMES, LIVER; NADP;

EID: 77954951078     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.033357     Document Type: Article

References (23)

1. Abell TL, Bernstein RK, Cutts T, Farrugia G, Forster J, Hasler WL, McCallum RW, Olden KW, Parkman HP, Parrish CR, et al. (2006) Treatment of gastroparesis: a multidisciplinary clinical review. Neurogastroenterol Motil 18:263-283.
2. Bakke OM and Segura J (1976) The absorption and elimination of metoclopramide in three animal species. J Pharm Pharmacol 28:32-39.
3. Bateman DN (1983) Clinical pharmacokinetics of metoclopramide. Clin Pharmacokinet 8:523-529.
4. Bateman DN, Kahn C, and Davies DS (1980) The pharmacokinetics of metoclopramide in man with observations in the dog. Br J Clin Pharmacol 9:371-377. (Pubitemid 10067058)
5. Cowan DA, Huizing G, and Beckett AH (1976) Identification of four new metabolic products of metoclopramide using mass spectrometry. Xenobiotica 6:605-616.
6. Desta Z, Wu GM, Morocho AM, and Flockhart DA (2002) The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6. Drug Metab Dispos 30:336-343.
7. Friedenberg FK and Parkman HP (2007) Advances in the management of gastroparesis. Curr Treat Options Gastroenterol 10:283-293.
8. Gunduz M, Argikar UA, Baeschlin D, Ferreira S, Hosagrahara V, and Harriman S (2010) Identification of a novel N-carbamoyl glucuronide: in vitro, in vivo and mechanistic studies. Drug Metab Dispos 38:361-367.
9. Iwuchukwu OF and Nagar S (2008) Resveratrol (trans-resveratrol, 3,5,4′-trihydroxy-trans-stilbene) glucuronidation exhibits atypical enzyme kinetics in various protein sources. Drug Metab Dispos 36:322-330.
10. Kenney C, Hunter C, Davidson A, and Jankovic J (2008) Metoclopramide, an increasingly recognized cause of tardive dyskinesia. J Clin Pharmacol 48:379-384.
11. Kim J, Riggs KW, and Rurak DW (2002) Effects of acute moderate hypoxemia on kinetics of metoclopramide and its metabolites in chronically instrumented sheep. Arch Pharm Res 25:709-717.
12. Lamparczyk H, Chmielewska A, Konieczna L, Plenis A, and Zarzycki PK (2001) RP-HPLC method with electrochemical detection for the determination of metoclopramide in serum and its use in pharmacokinetic studies. Biomed Chromatogr 15:513-517.
13. Maurich V, De Amichi M, De Micheli C, and Rossato P (1995) Identification and full characterization of a new metabolite of metoclopramide. Eur J Med Chem 30:757-762.
14. McDermed JE, Cohen JL, Joseph C, and Strum SB (1985) Clinical pharmacokinetics of high-dose metoclopramide in cancer patients receiving cisplatin therapy. J Clin Oncol 3:1400-1408.
15. Miller LG and Jankovic J (1990) Neurologic approach to drug-induced movement disorders: a study of 125 patients. South Med J 83:525-532.
16. Nowell S and Falany CN (2006) Pharmacogenetics of human cytosolic sulfotransferases. Oncogene 25:1673-1678.
17. Pasricha PJ, Pehlivanov N, Sugumar A, and Jankovic J (2006) Drug insight: from disturbed motility to disordered movement - a review of the clinical benefits and medicolegal risks of metoclopramide. Nat Clin Pract Gastroenterol Hepatol 3:138-148.
18. Smith DS and Ferris CD (2003) Current concepts in diabetic gastroparesis. Drugs 63:1339-1358.
19. Ung D and Nagar S (2007) Variable sulfation of dietary polyphenols by recombinant human sulfotransferase (SULT) 1A1 genetic variants and SULT1E1. Drug Metab Dispos 35:740-746.
20. Ung D, Parkman HP, and Nagar S (2009) Metabolic interactions between prokinetic agents domperidone and erythromycin: an in vitro analysis. Xenobiotica 39:749-756.
21. Vlase L, Leucuta A, Farcau D, and Nanulescu M (2006) Pharmacokinetic interaction between fluoxetine and metoclopramide in healthy volunteers. Biopharm Drug Dispos 27:285-289.
22. Yu J, Paine MJ, Maréchal JD, Kemp CA, Ward CJ, Brown S, Sutcliffe MJ, Roberts GC, Rankin EM, and Wolf CR (2006) In silico prediction of drug binding to CYP2D6: identification of a new metabolite of metoclopramide. Drug Metab Dispos 34:1386-1392.
23. Zaki NM, Mortada ND, Awad GA, and Abd ElHady SS (2006) Rapid-onset intranasal delivery of metoclopramide hydrochloride. Part II: Safety of various absorption enhancers and pharmacokinetic evaluation. Int J Pharm 327:97-103.